The Experts below are selected from a list of 2805 Experts worldwide ranked by ideXlab platform
Yukio Takeshima - One of the best experts on this subject based on the ideXlab platform.
-
muc4 a novel immunohistochemical marker identified by gene expression profiling differentiates pleural Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma
Modern Pathology, 2017Co-Authors: Vishwa Jeet Amatya, Kei Kushitani, Amany Sayed Mawas, Yoshihiro Miyata, Morihito Okada, Takumi Kishimoto, Kouki Inai, Yukio TakeshimaAbstract:Sarcomatoid mesothelioma, a histological subtype of malignant pleural mesothelioma, is a very aggressive tumor with a poor prognosis. Histological diagnosis of Sarcomatoid mesothelioma largely depends on the histomorphological feature of spindled tumor cells with immunohistochemical reactivity to cytokeratins. Diagnosis also requires clinico-radiological and/or macroscopic evidence of an extrapulmonary location to differentiate it from lung Sarcomatoid Carcinoma. Although there are promising immunohistochemical antibody panels to differentiate mesothelioma from lung Carcinoma, a consensus on the immunohistochemical markers that distinguish Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma has not been reached and requires further study. We performed whole gene expression analysis of formalin-fixed paraffin-embedded tissue from Sarcomatoid mesothelioma and lung Sarcomatoid Carcinoma and observed significant differences in the expression of MUC4 and other genes between Sarcomatoid mesothelioma and lung Sarcomatoid Carcinoma. Immunohistochemistry demonstrated that MUC4 was expressed in the spindled tumor cells of lung Sarcomatoid Carcinoma (21/29, 72%) but was not expressed in any Sarcomatoid mesothelioma (0/31, 0%). To differentiate Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma, negative MUC4 expression showed 100% sensitivity and 72% specificity and accuracy rate of 87%, which is higher than immunohistochemical markers such as calretinin, D2-40 and Claudin-4. Therefore, we recommend to include MUC4 as a novel and useful negative immunohistochemical marker for differentiating Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma.
-
value of immunohistochemistry in the differential diagnosis of pleural Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma
Histopathology, 2009Co-Authors: Yukio Takeshima, Vishwa Jeet Amatya, Kei Kushitani, Mayumi Kaneko, Kouki InaiAbstract:Aims: The differential diagnosis of pleural Sarcomatoid mesothelioma (SM) from lung Sarcomatoid Carcinoma (LSC) invading parietal pleura and chest wall is a challenging issue. The aim of this study was to identify useful antibodies that can be used for the differential diagnosis of pleural SM from LSC. Methods and results: Forty-five cases of pleural SM and 27 cases of LSC were immunohistochemically analysed by using 15 commercially available antibodies, including D2-40 and antibodies to calretinin, thrombomodulin, Wilms’ Tumour 1, carcinoembryonic antigen (CEA), Napsin A, thyroid transcription factor (TTF)-1, pan-cytokeratin, CAM5.2, epithelial membrane antigen, Ber-EP4, MOC-31, α-smooth muscle actin, h-caldesmon and desmin. The results revealed that D2-40 positivity was significantly higher in pleural SM (86.7%) than in LSC (25.9%). The positivity of the adenoCarcinoma markers, including CEA, Napsin A, and TTF-1, was low even in LSC. Conclusions: Evaluating the positivity and degree of staining of the well-known mesothelial marker D2-40 could be applied to differentiate pleural SM from the Sarcomatoid component of LSC, in addition to assessing clinical and radiological information.
-
differential diagnosis of Sarcomatoid mesothelioma from true sarcoma and Sarcomatoid Carcinoma using immunohistochemistry
Pathology International, 2008Co-Authors: Kei Kushitani, Vishwa Jeet Amatya, Yukio Takeshima, Osamu Furonaka, Akio Sakatani, Kouki InaiAbstract:Differentiation of Sarcomatoid mesothelioma from other Sarcomatoid tumors involving the pleura and other structures by light microscopy remains an important diagnostic challenge for surgical pathologists. The purpose of the present study was to investigate the utility of diagnostic immunohistochemistry for differentiating Sarcomatoid mesothelioma from its histological mimics: true sarcoma and pulmonary Sarcomatoid Carcinoma. A total of 39 specimens of mesotheliomas with Sarcomatoid components, 43 specimens of true sarcomas, and nine specimens of pulmonary Sarcomatoid Carcinomas were obtained from Japanese patients and examined using a 10-antibody panel (calretinin, WT1, AE1/AE3, CAM5.2, epithelial membrane antigen, desmin, alpha-smooth muscle actin, S-100 protein, CD34, and CD68). CAM5.2 had the highest sensitivity and specificity for differentiating Sarcomatoid mesothelioma from true sarcoma. The combination of CAM5.2, WT1, and AE1/AE3 is recommended for routine pathological diagnosis. Accurate clinical information is necessary for differentiating Sarcomatoid mesothelioma from Sarcomatoid Carcinoma.
Kouki Inai - One of the best experts on this subject based on the ideXlab platform.
-
muc4 a novel immunohistochemical marker identified by gene expression profiling differentiates pleural Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma
Modern Pathology, 2017Co-Authors: Vishwa Jeet Amatya, Kei Kushitani, Amany Sayed Mawas, Yoshihiro Miyata, Morihito Okada, Takumi Kishimoto, Kouki Inai, Yukio TakeshimaAbstract:Sarcomatoid mesothelioma, a histological subtype of malignant pleural mesothelioma, is a very aggressive tumor with a poor prognosis. Histological diagnosis of Sarcomatoid mesothelioma largely depends on the histomorphological feature of spindled tumor cells with immunohistochemical reactivity to cytokeratins. Diagnosis also requires clinico-radiological and/or macroscopic evidence of an extrapulmonary location to differentiate it from lung Sarcomatoid Carcinoma. Although there are promising immunohistochemical antibody panels to differentiate mesothelioma from lung Carcinoma, a consensus on the immunohistochemical markers that distinguish Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma has not been reached and requires further study. We performed whole gene expression analysis of formalin-fixed paraffin-embedded tissue from Sarcomatoid mesothelioma and lung Sarcomatoid Carcinoma and observed significant differences in the expression of MUC4 and other genes between Sarcomatoid mesothelioma and lung Sarcomatoid Carcinoma. Immunohistochemistry demonstrated that MUC4 was expressed in the spindled tumor cells of lung Sarcomatoid Carcinoma (21/29, 72%) but was not expressed in any Sarcomatoid mesothelioma (0/31, 0%). To differentiate Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma, negative MUC4 expression showed 100% sensitivity and 72% specificity and accuracy rate of 87%, which is higher than immunohistochemical markers such as calretinin, D2-40 and Claudin-4. Therefore, we recommend to include MUC4 as a novel and useful negative immunohistochemical marker for differentiating Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma.
-
value of immunohistochemistry in the differential diagnosis of pleural Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma
Histopathology, 2009Co-Authors: Yukio Takeshima, Vishwa Jeet Amatya, Kei Kushitani, Mayumi Kaneko, Kouki InaiAbstract:Aims: The differential diagnosis of pleural Sarcomatoid mesothelioma (SM) from lung Sarcomatoid Carcinoma (LSC) invading parietal pleura and chest wall is a challenging issue. The aim of this study was to identify useful antibodies that can be used for the differential diagnosis of pleural SM from LSC. Methods and results: Forty-five cases of pleural SM and 27 cases of LSC were immunohistochemically analysed by using 15 commercially available antibodies, including D2-40 and antibodies to calretinin, thrombomodulin, Wilms’ Tumour 1, carcinoembryonic antigen (CEA), Napsin A, thyroid transcription factor (TTF)-1, pan-cytokeratin, CAM5.2, epithelial membrane antigen, Ber-EP4, MOC-31, α-smooth muscle actin, h-caldesmon and desmin. The results revealed that D2-40 positivity was significantly higher in pleural SM (86.7%) than in LSC (25.9%). The positivity of the adenoCarcinoma markers, including CEA, Napsin A, and TTF-1, was low even in LSC. Conclusions: Evaluating the positivity and degree of staining of the well-known mesothelial marker D2-40 could be applied to differentiate pleural SM from the Sarcomatoid component of LSC, in addition to assessing clinical and radiological information.
-
differential diagnosis of Sarcomatoid mesothelioma from true sarcoma and Sarcomatoid Carcinoma using immunohistochemistry
Pathology International, 2008Co-Authors: Kei Kushitani, Vishwa Jeet Amatya, Yukio Takeshima, Osamu Furonaka, Akio Sakatani, Kouki InaiAbstract:Differentiation of Sarcomatoid mesothelioma from other Sarcomatoid tumors involving the pleura and other structures by light microscopy remains an important diagnostic challenge for surgical pathologists. The purpose of the present study was to investigate the utility of diagnostic immunohistochemistry for differentiating Sarcomatoid mesothelioma from its histological mimics: true sarcoma and pulmonary Sarcomatoid Carcinoma. A total of 39 specimens of mesotheliomas with Sarcomatoid components, 43 specimens of true sarcomas, and nine specimens of pulmonary Sarcomatoid Carcinomas were obtained from Japanese patients and examined using a 10-antibody panel (calretinin, WT1, AE1/AE3, CAM5.2, epithelial membrane antigen, desmin, alpha-smooth muscle actin, S-100 protein, CD34, and CD68). CAM5.2 had the highest sensitivity and specificity for differentiating Sarcomatoid mesothelioma from true sarcoma. The combination of CAM5.2, WT1, and AE1/AE3 is recommended for routine pathological diagnosis. Accurate clinical information is necessary for differentiating Sarcomatoid mesothelioma from Sarcomatoid Carcinoma.
C J L M Meijer - One of the best experts on this subject based on the ideXlab platform.
-
analysis by comparative genomic hybridization of epithelial and spindle cell components in Sarcomatoid Carcinoma and carcinosarcoma histogenetic aspects
The Journal of Pathology, 1999Co-Authors: Rolf Torenbeek, Mario A J A Hermsen, Jan P A Baak, Gerrit A. Meijer, C J L M MeijerAbstract:Sarcomatoid Carcinomas and carcinosarcomas are histologically malignant biphasic neoplasms with an epithelial and a spindle cell component. Both a polyclonal and a monoclonal origin have been postulated for these tumours, but the latter has been favoured. For carcinosarcoma, the stem cell from which the epithelial and mesenchymal components are derived is expected to be more immature than the epithelial stem cell from which different components of Sarcomatoid Carcinoma originate, since in the latter, immunohistochemical or ultrastructural epithelial characteristics are still detectable. In the present study, comparative genomic hybridization was used to test the hypothesis that both tumour components in Sarcomatoid Carcinoma have more chromosomal aberrations in common than those in carcinosarcoma. From three Sarcomatoid Carcinomas originating from the urinary bladder and two carcinosarcomas from the pharynx, the epithelial and spindle cell components were microdissected and analysed for their respective chromosomal aberrations, using comparative genomic hybridization. High-level homology was seen in chromosomal aberrations between the different components in each tumour. This level of homology was even higher in the carcinosarcomas (65 and 91 per cent) than in both Sarcomatoid Carcinomas (21–51 per cent). The different phenotypic components of both Sarcomatoid Carcinoma and carcinosarcoma show a large overlap of chromosomal aberrations, strongly suggesting a monoclonal origin for all of these tumours. These findings do not support the hypothesis that the divergence between epithelial and spindle cell components occurs at an earlier stage in carcinosarcomas than in Sarcomatoid Carcinoma. Copyright © 1999 John Wiley & Sons, Ltd.
-
Sarcomatoid Carcinoma of the urinary bladder clinicopathologic analysis of 18 cases with immunohistochemical and electron microscopic findings
The American Journal of Surgical Pathology, 1994Co-Authors: R Torenbeek, C E M Blomjous, P C De Bruin, D W W Newling, C J L M MeijerAbstract:Sarcomatoid Carcinoma is a rare tumor in the urinary bladder and accounts for approximately 0.3% of all bladder malignancies. In this study, the clinicopathologic findings of 18 cases are described. Distribution of sex and age and clinical symptoms are not distinctive from transitional cell Carcinoma. The tumor behaves as a high-grade malignancy with advanced initial stage and unfavorable outcome. Surgery is the therapy of choice. Histological differentiation from true sarcoma may be difficult. Recognition rests on the co-existence of an overt Carcinomatous component or demonstration of the epithelial nature by immunohistochemistry or electron microscopy.
Vishwa Jeet Amatya - One of the best experts on this subject based on the ideXlab platform.
-
muc4 a novel immunohistochemical marker identified by gene expression profiling differentiates pleural Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma
Modern Pathology, 2017Co-Authors: Vishwa Jeet Amatya, Kei Kushitani, Amany Sayed Mawas, Yoshihiro Miyata, Morihito Okada, Takumi Kishimoto, Kouki Inai, Yukio TakeshimaAbstract:Sarcomatoid mesothelioma, a histological subtype of malignant pleural mesothelioma, is a very aggressive tumor with a poor prognosis. Histological diagnosis of Sarcomatoid mesothelioma largely depends on the histomorphological feature of spindled tumor cells with immunohistochemical reactivity to cytokeratins. Diagnosis also requires clinico-radiological and/or macroscopic evidence of an extrapulmonary location to differentiate it from lung Sarcomatoid Carcinoma. Although there are promising immunohistochemical antibody panels to differentiate mesothelioma from lung Carcinoma, a consensus on the immunohistochemical markers that distinguish Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma has not been reached and requires further study. We performed whole gene expression analysis of formalin-fixed paraffin-embedded tissue from Sarcomatoid mesothelioma and lung Sarcomatoid Carcinoma and observed significant differences in the expression of MUC4 and other genes between Sarcomatoid mesothelioma and lung Sarcomatoid Carcinoma. Immunohistochemistry demonstrated that MUC4 was expressed in the spindled tumor cells of lung Sarcomatoid Carcinoma (21/29, 72%) but was not expressed in any Sarcomatoid mesothelioma (0/31, 0%). To differentiate Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma, negative MUC4 expression showed 100% sensitivity and 72% specificity and accuracy rate of 87%, which is higher than immunohistochemical markers such as calretinin, D2-40 and Claudin-4. Therefore, we recommend to include MUC4 as a novel and useful negative immunohistochemical marker for differentiating Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma.
-
value of immunohistochemistry in the differential diagnosis of pleural Sarcomatoid mesothelioma from lung Sarcomatoid Carcinoma
Histopathology, 2009Co-Authors: Yukio Takeshima, Vishwa Jeet Amatya, Kei Kushitani, Mayumi Kaneko, Kouki InaiAbstract:Aims: The differential diagnosis of pleural Sarcomatoid mesothelioma (SM) from lung Sarcomatoid Carcinoma (LSC) invading parietal pleura and chest wall is a challenging issue. The aim of this study was to identify useful antibodies that can be used for the differential diagnosis of pleural SM from LSC. Methods and results: Forty-five cases of pleural SM and 27 cases of LSC were immunohistochemically analysed by using 15 commercially available antibodies, including D2-40 and antibodies to calretinin, thrombomodulin, Wilms’ Tumour 1, carcinoembryonic antigen (CEA), Napsin A, thyroid transcription factor (TTF)-1, pan-cytokeratin, CAM5.2, epithelial membrane antigen, Ber-EP4, MOC-31, α-smooth muscle actin, h-caldesmon and desmin. The results revealed that D2-40 positivity was significantly higher in pleural SM (86.7%) than in LSC (25.9%). The positivity of the adenoCarcinoma markers, including CEA, Napsin A, and TTF-1, was low even in LSC. Conclusions: Evaluating the positivity and degree of staining of the well-known mesothelial marker D2-40 could be applied to differentiate pleural SM from the Sarcomatoid component of LSC, in addition to assessing clinical and radiological information.
-
differential diagnosis of Sarcomatoid mesothelioma from true sarcoma and Sarcomatoid Carcinoma using immunohistochemistry
Pathology International, 2008Co-Authors: Kei Kushitani, Vishwa Jeet Amatya, Yukio Takeshima, Osamu Furonaka, Akio Sakatani, Kouki InaiAbstract:Differentiation of Sarcomatoid mesothelioma from other Sarcomatoid tumors involving the pleura and other structures by light microscopy remains an important diagnostic challenge for surgical pathologists. The purpose of the present study was to investigate the utility of diagnostic immunohistochemistry for differentiating Sarcomatoid mesothelioma from its histological mimics: true sarcoma and pulmonary Sarcomatoid Carcinoma. A total of 39 specimens of mesotheliomas with Sarcomatoid components, 43 specimens of true sarcomas, and nine specimens of pulmonary Sarcomatoid Carcinomas were obtained from Japanese patients and examined using a 10-antibody panel (calretinin, WT1, AE1/AE3, CAM5.2, epithelial membrane antigen, desmin, alpha-smooth muscle actin, S-100 protein, CD34, and CD68). CAM5.2 had the highest sensitivity and specificity for differentiating Sarcomatoid mesothelioma from true sarcoma. The combination of CAM5.2, WT1, and AE1/AE3 is recommended for routine pathological diagnosis. Accurate clinical information is necessary for differentiating Sarcomatoid mesothelioma from Sarcomatoid Carcinoma.
Qi Bo Wang - One of the best experts on this subject based on the ideXlab platform.
-
clinicopathological characteristics and outcome of primary Sarcomatoid Carcinoma and carcinosarcoma of the liver
Journal of Gastrointestinal Surgery, 2012Co-Authors: Qi Bo Wang, Jian Ming Weng, Qiu Liang WuAbstract:Background Primary Sarcomatoid Carcinoma (SC) and carcinosarcoma (CS) of the liver are rare tumors.
-
clinicopathological characteristics and outcome of primary Sarcomatoid Carcinoma and carcinosarcoma of the liver
Journal of Gastrointestinal Surgery, 2012Co-Authors: Qi Bo Wang, Jian Ming Weng, Bo Kang Cui, Ji Liang Qiu, Xiaojun LinAbstract:Primary Sarcomatoid Carcinoma (SC) and carcinosarcoma (CS) of the liver are rare tumors. From November 1999 to June 2011, clinicopathological features and outcome of 10 SC and 14 CS patients were retrospectively studied. In the SC group, six patients had hepatocellular Carcinoma and four had cholangiocellular Carcinoma, while in the CS group, it was nine and five patients, respectively. All cases of the sarcomatous components were vimentin-positive. Pan-cytokeratin were stained in sarcomatous components of the SC group, but not in the CS group. The sarcomatous component in the SC group was negative for desmin, myoglobin, HHF35, SMA, CD68, Mac387, AAT, CD34, and S100. In the CS group, the sarcomatous components in six cases were malignant fibrous histiocytomas, six were fibrosarcomas, and two were rhabdomyosarcomas. Median survival times were 9.6 and 4.8 months for the SC and CS groups, respectively (P = 0.483). In univariate analysis, favorable predictors of overall survival were asymptomatic, Child–Pugh class A, no distant metastasis, and radical resection. SC and CS were highly aggressive malignancies with similar poor survival regardless of the histological and immunohistochemical findings. Early detection through regular physical examination and treatment with radical resection may improve the outcome of those patients.
